Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
BROMODOMAIN INHIBITORS REDUCE...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO
Bibliographic Details
Main Authors:
Hammitzsch, A
,
de Wit, J
,
Ridley, A
,
Al-Mossawi, M
,
Knapp, S
,
Bowness, P
Format:
Journal article
Published:
2014
Holdings
Description
Similar Items
Staff View
Similar Items
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
by: Hammitzsch, A, et al.
Published: (2015)
Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
by: Hammitzsch, A, et al.
Published: (2018)
Elevated type-17 cytokines are present in Axial Spondyloarthritis stool
by: Brough, I, et al.
Published: (2024)
SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS
by: De Wit, J, et al.
Published: (2014)
miR-10b-5p is a novel Th17 regulator present in Th17 cells from Ankylosing Spondylitis
by: Chen, L, et al.
Published: (2017)